ASRS 2022: On-Label Agents Increasingly Used for Diabetic Macular Edema, Though Many Discontinue Treatment
Three-quarters of the 15 percent of patients who switched agents went from bevacizumab to an on-label agent after a mean of 50 weeks
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.